Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 10/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24844799 | 0.86 | CYP11B1 (0.47) | CYP11B1CYP11B2TBXAS1CYP19A1 | |
| SCHEMBL24844793 | 0.83 | TBXAS1 (0.56) | CYP11B1CYP11B2TBXAS1CYP19A1CYP1A2 | |
| SCHEMBL24844912 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2TBXAS1CYP19A1CYP1A2 | |
| SCHEMBL24845255 | 0.74 | CYP11B1 (0.52) | CYP11B1CYP11B2TBXAS1CYP19A1 | |
| SCHEMBL24844772 | 0.74 | CYP11B1 (0.52) | CYP11B1CYP11B2TBXAS1CYP19A1 | |
| SCHEMBL24844760 | 0.74 | CYP11B1 (0.52) | CYP11B1CYP11B2TBXAS1CYP19A1 | |
| SCHEMBL3317473 | 0.71 | CYP11B1 (0.60) | CYP11B1CYP11B2TBXAS1CYP1A2USP2 | |
| SCHEMBL24844798 | 0.71 | TBXAS1 (0.53) | CYP11B1CYP11B2TBXAS1CYP19A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10529727 | 0.71 | TBXAS1 (0.53) | TBXAS1CYP19A1 | |
| SCHEMBL7077754 | 0.70 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336638-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | ZHUGE, Guoqin (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-115557898-B | Imidazole compound, intermediate and application thereof | 诸葛国琴 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557898-A | Imidazole compound, intermediate and application thereof | 诸葛国琴 | 2023-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336638-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | PINK1, TFPI, PLAT | CYP11B1 117/4885CYP11B2 133/4885TBXAS1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.